source
- J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trialJohnson & Johnson's recent $3 billion purchase of Halda Therapeutics added an oral prostate cancer candidate, JNJ-6143, to its pipeline. The drug targets a cancer-specific protein to trigger cell d…
- Australian clinical trials attract more U.S. sponsors amid regulatory uncertaintyCROs are reporting faster startup timelines, predictable regulation, and tax incentives as reasons for increasing interest in conducting clinical trials in Australia. State-level incentives in Que…